HIVE vs CD
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 02, 2026
HIVE
40.6
AI Score
VS
HIVE Wins
CD
28.9
AI Score
Investment Advisor Scores
CD
29score
Recommendation
SELL
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | HIVE | CD | Winner |
|---|---|---|---|
| Revenue | 79.12M | 970,752 | HIVE |
| Net Income | -142.91M | -2.46M | CD |
| Gross Margin | -37.3% | 45.4% | CD |
| Net Margin | -180.6% | -253.1% | HIVE |
| ROE | -33.8% | -5.3% | CD |
| ROA | -15.5% | -5.0% | CD |
| Total Assets | 924.64M | 49.13M | HIVE |
| Cash | 208.04M | 30.97M | HIVE |
| Current Ratio | 1.96 | 27.53 | CD |
Relative Price Performance (Last 90 Days)
HIVE 1M: +7.2%
· 3M: -13.8%
CD 1M: +96.3%
· 3M: +46.4%
Current Technical Phase
HIVE
DistributionTrim / tighten stop
Price near a flattening SMA50 (slope -2.7%) with fading momentum, RSI 44
CD
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 67
Fundamentals Snapshot
| Metric | HIVE | CD |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -5.7 | 0.0 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.7% | 1.0% |
| Gross Margin | 0.4% | 0.6% |
| Operating Margin | -0.6% | -3.0% |
| EPS | -1.39 | -0.04 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.